Moleculin Biotech (Nasdaq: MBRX) said it has completed an underwritten public offering raising $9.3 million. The deal included 12,376,667 shares of common stock (or equivalent prefunded warrants) and accompanying warrants. The warrants have an exercise price of $0.75 per share and expire five years after the initial exercise date.

LyondellBasell reported its second-quarter 2026 results, posting adjusted EBITDA of $2.1 billion and adjusted diluted earnings per share of $4.30. Both figures were well above typical market expectations. The company attributed the performance to optimization of its higher-value polyolefins product mix and improved operating efficiency in North America. The results point to a recovery in profitability across the global basic chemicals industry and are viewed as a positive signal for traditional chemical and industrial raw-material assets.

Parex Resources (TSX: PXT) reported second-quarter 2026 results, including adjusted EBITDA of C$192 million. An independent reserves report showed proved developed producing (PDP) and 1P reserves rose by more than 80% versus year-end 2025. The company reaffirmed its 2026 “StepChange” production and financial guidance and declared a regular Q3 2026 dividend of C$0.385 per share.

Inno Holdings Inc. said trading in its shares on the Nasdaq Capital Market is expected to resume at or around noon, eastern time on July 31, 2026, instead of at the market open as previously indicated. The stock had been halted on June 12 under Nasdaq’s T12 code after unusual trading activity. As of July 29, the company had 2,520,581 shares of common stock issued and outstanding. The company said the halt’s lift is procedural and does not reflect any fundamental change.

Caldwell Investment Management Ltd. said it will move the ETF units of the Caldwell U.S. Dividend Advantage Fund (UDA) from the Toronto Stock Exchange to the Canadian Securities Exchange. The fund is expected to voluntarily delist from the TSX after market close on Aug. 13, 2026 and begin trading on the CSE on Aug. 14. The change is limited to the listing venue and does not alter the fund’s investment strategy, portfolio holdings or management team. No changes were disclosed to the management expense ratio, liquidity or market-making arrangements.

Eldorado Gold Corporation (TSX: ELD, NYSE: EGO) said the Toronto Stock Exchange has approved its notice to renew a normal course issuer bid. The company may buy back up to 13,065,993 common shares over the next year, representing 5% of the 261,319,863 shares outstanding as at July 27, 2026. Purchases on the TSX will be capped at 194,581 shares per day under TSX rules. The buyback is described as a routine capital return and does not involve new financing or a change in the business.

Home Federal Bancorp, Inc. of Louisiana reported fiscal-year results for the year ended June 30, 2026, with net income of $6.174 million, up 58.8% year over year. Basic earnings per share came in at $2.05, up from $1.27 a year earlier. The regional bank’s sharp profit growth reflects improvements in asset quality and net interest margin management. The results are viewed as a fundamental positive for the regional banking sector.

JIADE Limited (Nasdaq: JDZG) said trading in its Class A ordinary shares, halted since June 4, 2026 under Nasdaq’s T12 code for additional information requests, will resume at 12:00 p.m. Eastern Time on July 31, 2026. The company said it submitted written responses and supplemental materials to Nasdaq on June 10, June 17 and July 2. JIADE said it provides education support services, including pre-enrollment guidance, exam training and application support.

Waldencast plc (NASDAQ: WALD) said it has completed the sale of its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint in a transaction valued at up to $460 million, subject to negotiated deductions and customary adjustments. The company said the move is intended to strengthen its balance sheet and sharpen its strategic focus on accelerating the global growth of Milk Makeup. The transaction is positioned as a company-level divestiture catalyst that could affect expectations for WALD’s fundamentals and valuation.